The efficacy assessment of Silversulfadiazine topical cream containing Epidermal growth factor (EGF) on burn wounds healing (type II)

?Comparison of efficacy of Silversulfadiazine topical cream containing Epidermal growth factor (EGF) and Silversulfadiazine topical cream without Epidermal growth factor (EGF) on burn wounds healing (type II).

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220424054633N1

Enrollment

Registered

2022-06-06

Start date

2022-06-10

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Grade II burn wounds. Burns of multiple regions, no more than second-degree burns mentioned

Interventions

Intervention 1: Intervention group: Silver Sulfadiazine 1% containing 0.001% Epidermal Growth Factor topical cream was used and the burn wound area is covered by sterile gauze, very 12 hours wound are

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: People with grade II burn wounds. Burn area must be bilateral, in 2 hands or 2 legs, etc.

Exclusion criteria

Exclusion criteria: Having any underlying diseases that interfere with wound healing such as chronic kidney disease, diabetes, liver disease, any diseases of immunodeficiency, and smoking. Having cancer or background of Cancer Allergy to Epidermal Growth Factor, silver sulfadiazin or any material in the formulation. Pregnancy Breastfeeding

Design outcomes

Primary

Measure	Time frame
Wound size. Timepoint: At the beginning of the study (Before intervention), end of first week, end of second week, end of third week, end of fourth week. Method of measurement: Photography and Image J software.;Epidermis Thickness. Timepoint: At the beginning of the study (Before intervention), end of first week, end of second week, end of third week, end of fourth week. Method of measurement: Biometry.;Dermis Thickness. Timepoint: At the beginning of the study (Before intervention), end of the first week, end of the second week, end of the third week, end of the fourth week. Method of measurement: Biometry.;Wound healing velocity. Timepoint: At the beginning of the study (Before intervention), end of the first week, end of the second week, end of the third week, end of the fourth week. Method of measurement: Photography and Image J software.	—

Measure

Time frame

Wound size. Timepoint: At the beginning of the study (Before intervention), end of first week, end of second week, end of third week, end of fourth week. Method of measurement: Photography and Image J software.;Epidermis Thickness. Timepoint: At the beginning of the study (Before intervention), end of first week, end of second week, end of third week, end of fourth week. Method of measurement: Biometry.;Dermis Thickness. Timepoint: At the beginning of the study (Before intervention), end of the first week, end of the second week, end of the third week, end of the fourth week. Method of measurement: Biometry.;Wound healing velocity. Timepoint: At the beginning of the study (Before intervention), end of the first week, end of the second week, end of the third week, end of the fourth week. Method of measurement: Photography and Image J software.

—

Secondary

Measure	Time frame
Improving Life's Quality. Timepoint: ?At the beginning of the study and two week after finishing the study. Method of measurement: Interviewing and giving out self assessment form.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Golkar

Pasture Institute of Iran

majid.golkar@gmail.com+98 21 6411 2267

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026